非霍奇金淋巴瘤单克隆抗体治疗的研究进展  

Research Progress on Monoclonal Antibody Therapy for Non-Hodgkin's Lymphoma

作　　者：温宁笑 袁红梅 

机构地区：[1]武警江西省总队医院,江西南昌330030

出　　处：《现代诊断与治疗》2010年第4期221-223,共3页Modern Diagnosis and Treatment

摘　　要：单克隆抗体应用于临床治疗恶性淋巴瘤目前已经取得了明显成效,与传统治疗相比,具有靶向性、不良反应小、能达到体内肿瘤细胞的微量残留等特点。新的抗CD20单克隆抗体为非霍奇金淋巴瘤治疗带来了新的发展,对以美罗华为代表单克隆抗体治疗恶性淋巴瘤的耐药问题带来了新的突破,提出了新策略。Monoclonal antibody treatment has made great achievement in patients with malignant lymphomas.Comparing with traditional treatment,its advantages are targeted property and little side effect.It also could achieve mininal residal of tumor cell in vivo.The new anti-CD20 monoclonal antibody provides new development for treatment of non-Hodgkin＇s lymphoma and introduces a new strategy to the drug resistance.

关 键 词：单克隆抗体 淋巴瘤 抗CD20 非霍奇金淋巴瘤 

分 类 号：R733.4[医药卫生—肿瘤]